Cumulus Neuroscience to Present Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference

July 11, 2023
  • Interim analysis on CNS-101 with mild Alzheimer’s dementia participants in home-based functional neurophysiology studies.
  • Poster presentations scheduled for the Technology and Dementia Preconference on Saturday, July 15th at 7:00 A.M. CEST and main Alzheimer’s Association International Conference (AAIC) Annual Meeting on Monday, July 17 at 8:45 A.M. CEST in Amsterdam, Netherlands.

BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 11, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, will present interim data from their CNS-101 study at the Alzheimer’s Association International Conference 2023 in Amsterdam, Netherlands. The study is being conducted in collaboration with the University of Cambridge and Trinity Biomedical Science Institute.

Titled “Feasibility of real-world endpoints of functional neurophysiology in Alzheimer’s disease dementia,” the poster was accepted by the AAIC Scientific Program Committee.

“Today, traditional biomarkers are effective in tracking disease progression in clinical studies, however these do not scale to support large real-world studies, require patients to attend clinic appointments which are costly and can be inconvenient and stressful for patients,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “Digital biomarkers have proven to be scalable, however, to date they have lacked objectivity and grounding in clinical measures. We are deeply grateful to the study participants and collaborators who dedicate their time with the hope of better understanding this life-changing neurodegenerative disease and accelerating much needed new treatments.”

Alzheimer’s is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, difficulty with language and communication, mood swings, and changes in behavior and personality. Currently, there is no known cure for Alzheimer’s.

Cumulus poster presentation details are as follows:

  • Technology and Dementia Preconference
    • Title: TECH-P-108 Feasibility of real-world endpoints of functional neurophysiology in Alzheimer’s disease dementia
    • Date & Time: Saturday, July 15, 2023: 7:00 AM – 5:00 PM CEST
    • Poster Number: 82187
    • Session: Technology and Dementia Posters
  • Alzheimer’s Association International Conference (AAIC)
    • Title: P2-295 Feasibility of real-world endpoints of functional neurophysiology in Alzheimer’s disease dementia
    • Date & Time: Monday, July 17, 2023: 8:45 AM – 4:15 PM CEST
    • Poster Number: 78914
    • Session: P2-06 Biomarkers: Biomarkers (non-neuroimaging)

A second co-authored poster with Cumulus and Boston University was also accepted, titled “Feasibility of implementing wearable technologies for in-home assessment of behavioral and event-related potential responses after sleep and wakefulness in Alzheimer disease.”

Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit

Notes to Editors

With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.

Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient’s home – all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.

The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.